InnoCare and Eli Lilly sign potential US$3.35bn drug-development deal
Chinese biotech company InnoCare Pharma has agreed a research collaboration and licensing partnership with Eli Lilly worth up to US$3.35bn. Analysts say the arrangement reflects a wider shift in China’s biotech sector from licensing individual drug candidates towards broader co-development and platform partnerships.
Chinese biotech company InnoCare Pharma has signed a research collaboration and licensing agreement with US pharmaceutical group Eli Lilly that could be worth up to US$3.35bn. InnoCare said its drug-discovery platform would be used to identify and advance compounds against as many as five targets. The companies did not specify the therapeutic areas, saying the medicines would address significant unmet medical needs.
Under the agreement, Eli Lilly will pay InnoCare US$100m upfront. The Beijing-based cancer-drug developer could receive up to US$3.25bn in development and commercialisation milestone payments, as well as tiered royalties in the single digits based on annual net product sales. The deal was described by analysts as evidence of a change in the way Chinese biotech companies engage with global pharmaceutical groups.
Cui Cui, head of Asia healthcare research at Jefferies, said the sector was moving from replication driven by speed towards differentiated innovation. Chinese developers had traditionally relied on out-licensing, selling rights to early-stage drug candidates so international partners could handle development and commercialisation. Cui said companies were increasingly moving towards co-development agreements and broader partnerships built around discovery platforms.
She pointed to a recent collaboration between Jiangsu Hengrui Pharmaceutical and Bristol Myers Squibb worth up to US$15.2bn. That agreement included US$600m in upfront payments and involved 13 early-stage programmes across oncology, haematology and immunology, with five assets to be jointly developed. Nomura analyst Jialin Zhang said Chinese research accounted for 29 of 96 late-breaking abstracts scheduled for the 2026 European Society for Medical Oncology Congress in Madrid.
Five of the 12 studies selected for the congress’s presidential symposium were also from China, figures Zhang said reflected the growing scale and quality of the country’s innovative drug research.
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.